S&P 500 Gains and Losses Today: Gartner Stock Plunges; Palantir, Axon Surge After Earnings

U.S. equities declined on Tuesday, with the S&P 500 falling 0.5% following an unexpected services sector slowdown and ongoing trade concerns. Market performance was bifurcated: Gartner plummeted nearly 28% after cutting its full-year outlook due to soft IT spending, while Vertex Pharmaceuticals dropped 21% on an R&D setback and TransDigm fell 12% on aerospace weakness. Conversely, Axon Enterprise surged over 16% and Palantir Technologies gained 7.8% after both companies reported strong quarterly results driven by robust demand for their AI solutions, with Leidos Holdings also rising 7.5% on defense demand and AI integration.

Analysis

The market displayed significant divergence on August 5, 2025, with the S&P 500 declining 0.5% on macroeconomic concerns stemming from an unexpected slump in the services sector. This backdrop sharply contrasted with firm-specific performance, creating clear winners and losers. Companies exposed to discretionary corporate spending and R&D setbacks faced severe punishment; Gartner (IT) plummeted nearly 28% after cutting its full-year guidance due to soft demand in its core research unit, signaling broader caution in business spending. Similarly, Vertex Pharmaceuticals (VRTX) dropped 21% not on current performance, which actually beat estimates, but on a forward-looking catalyst: the discontinuation of a promising Phase 2 pain treatment. TransDigm Group (TDG) fell 12% on missed estimates attributed to inventory destocking in its commercial aerospace segment. Conversely, companies demonstrating tangible growth from the artificial intelligence secular trend were strongly rewarded. Axon Enterprise (AXON) surged over 16% and Palantir Technologies (PLTR) gained 7.8% after both surpassed quarterly estimates and raised their 2025 outlooks, citing robust demand for their respective AI-driven software platforms. Leidos Holdings (LDOS) also advanced 7.5%, benefiting from a combination of AI advancements and heightened demand for its defense systems amid geopolitical tensions.

Key Decisions for Investors

• Investors should prioritize companies with demonstrated, revenue-generating AI applications, as shown by the outperformance of Axon and Palantir, over firms with more speculative AI narratives.
• Gartner's severe guidance cut serves as a negative bellwether for corporate IT spending, warranting a review of holdings in enterprise software and services for vulnerability to a potential spending slowdown.
• The sharp decline in Vertex shares, despite strong current sales, highlights the binary risk of clinical trial outcomes in biotech; it may be prudent to hedge or re-evaluate positions in companies with heavy reliance on a single developmental pipeline.
• The contrasting performance between TransDigm's commercial aerospace weakness and Leidos's defense strength suggests a bifurcation in the sector; consider overweighting defense contractors benefiting from geopolitical demand while remaining cautious on commercial suppliers facing inventory headwinds.